✦ LIBER ✦

A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies

✍ Scribed by Julie Bauman; Claire Verschraegen; Steven Belinsky; Carolyn Muller; Teresa Rutledge; M. Fekrazad; Meera Ravindranathan; Sang-Joon Lee; Dennie Jones

Publisher: Springer
Year: 2011
Tongue: English
Weight: 288 KB
Volume: 69
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-011-1729-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of cetuximab, erlotinib, a

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors

✍ Chia-Chi Lin; Emiliano Calvo; Kyriakos P. Papadopoulos; Amita Patnaik; John Sara 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 278 KB

A phase I study of bortezomib and temozo

A phase I study of bortezomib and temozolomide in patients with advanced solid tumors

✍ J. Portnow; P. Frankel; S. Koehler; P. Twardowski; S. Shibata; C. Martel; R. Mor 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 384 KB

Phase I trial of oral MAC-321 in subject

Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors

✍ A. C. Lockhart; R. Bukowski; M. L. Rothenberg; K. K. Wang; W. Cooper; J. Grover; 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 212 KB

A phase I study of obatoclax mesylate, a

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies

✍ Paul K. Paik; Charles M. Rudin; Andrew Brown; Naiyer A. Rizvi; Naoko Takebe; Wil 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 273 KB

Phase I study to evaluate multiple regim

Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors : A potential broadly active regimen for advanced solid tumor malignancies

✍ Sridhar Mani; Nicholas J. Vogelzang; Donna Bertucci; Walter M. Stadler; Richard 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

A phase I dose-escalation and bioavailab

A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin

✍ M. Ranson; H. Shaw; J. Wolf; M. Hamilton; S. McCarthy; E. Dean; A. Reid; I. Juds 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 340 KB